Table 1.
Polymeric Nanocapsules Obtained and Characterized in vivo for Delivery of Various Anticancer Compounds
| Nanocarriers | Drug | Route of Administration | Animal Model | Targeting |
|---|---|---|---|---|
| PCL nanocarriers127 | 2-(2-Methoxyphenyl)-3-((Piperidin-1-yl)ethyl)thiazolidin-4-one | Orally | Healthy Wistar rats | Passive |
| PCL nanocarriers128 | Diphenyl diselenide | i.g. | Wistar rats, healthy or tumor-bearing rats after injection of C6 (rat glioma) cells in the right striatum | Passive |
| Polyurethane nanocarriers129 | Doxorubicin | - | Zebrafish | Active – mitochondria |
| PEGylated polypyrrole nanocarriers79 | Doxorubicin | i.v. | Tumor-bearing athymic nude mice after subcutaneous injection of Skov3 (human ovarian carcinoma) cells | Active – folate receptor |
| Spherical SiO2 structured PDADMAC, PAZO NaGdF4, Yb, Tm@NaYF4@NaGdF4, Nd@NaYF130 | Doxorubicin | i.v. | Tumor-bearing BALB/c nude mice after subcutaneous injection of U87-MG (human glioblastoma) cells | Light-triggered drug delivery |
| Poly-L-arginine nanocarriers131 | Elisidepsin | Orally | Healthy mice | Passive |
| PEGylated b-poly(L-aspartic acid) nanocarriers132 | Erlotinib | i.v. | Tumor-bearing BALB/c nude mice after subcutaneous injection of HCC-827 (human lung adenocarcinoma) cells | Passive |
| PEGylated lipid based nanosuspention133 | Etoposide | i.v. | Healthy Kunming mice and tumor-bearing BALB/c mice after subcutaneous injection of A20 (murine lymphoma) cells | Passive |
| PCLlipid core nanocarriers134 | Eugenol or acetyl eugenol | Orally or i.p. | Tumor-bearing C57Bl6 mice after subcutaneous injection of B16F10 (murine melanoma) cells | Passive |
| PEGylated lipid squalene nanocarriers135 | Gemcitabine | Convection-enhanced delivery (the infusion of therapeutic molecules directly into the brain) | Healthy Sprague- Dawley or tumor-bearing Fischer 344 rats after intracranial implantation of RG2 (rat glioma) cells | Passive |
| PEGylated PLGA nanocarriers136 | Glabrescione b | i.v. | Tumor-bearing SCID/Beige mice after subcutaneous injection of PANC-1 (human pancreas carcinoma) cells | Passive |
| PCLnanocarriers137 | Methotrexate | Orally or i.v. | Healthy or tumor-bearing C57Bl/6 mice after intracranial implantation of GL261 (murine glioma) cells | Passive |
| Chitosan and Eudragit S100 nanocarriers138 | Psoralidin | Orally | Healthy Sprague-Dawley rats | Passive |
| PCL nanocarriers139 | Resveratrol | i.p. | Tumor-bearing C57BL/6J mice after subcutaneous injection of B16F10 (murine melanoma) cells | Passive |
| PLA nanocarriers140 | Tamoxifen | i.v. | Tumor-bearing Swiss albino mice after subcutaneous injection of MCF-7 (human breast cancer estrogen receptor-positive) cells | Passive |
| Polydopamine nanocarriers141 | Zeolitic nanocrystals | i.p. | Healthy Sprague- Dawley rats | Passive |
Abbreviations: i.g., intragastric; i.p., intraperitoneal; i.v., intravenous; PCL, poly-e-caprolactone; PEG, poly(ethylene glycol); PLA, poly(lactide).